Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin PIPAC for Peritoneal Metastases (PIPOX)
NCT03294252Phase 2Terminated
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- May 2017
- Primary completion
- Feb 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin in peritoneal carcinomatosis (PC), colorectal cancer (CRC), gastric cancer (GC), small intestine cancer, sponsored by Institut Cancérologique de l'Ouest. Started May 2017; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
peritoneal carcinomatosis (PC)colorectal cancer (CRC)gastric cancer (GC)small intestine cancer
Beyond the preview
Go deeper on NCT03294252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03294252.